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(FSDs) is generally considered to be a multifactorial interplay
between psychological, biological, and social factors. One of the
most investigated biological factors is stress responsive system
dysfunction. Despite more than twenty years of research of the
autonomic nervous system and the hypothalamic-pituitary-adrenal
axis, however, it is yet unknown whether dysfunctions in these
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doi:10.1016/j.jpsychores.2009.12.004are generic or FSD-specific. In this review, we will give an overview
of available evidence on whether or not alterations in these stress
responsive systems can be considered causal risk factors of FSDs.
We conclude that although not necessary factors for FSDs in
general, lowered cardiac vagal activity and hypocortisolism may be
pivotal in the etiology and treatment strategy in subgroups of
subjects with a FSD. Such subgroups need to be better identified.
© 2010 Elsevier Inc. All rights reserved.Keywords: Autonomic nervous system; Functional somatic symptoms; Hypothalamus-pituitary-adrenal axis; Somatoform; Stress; Functional somatic
syndromesIntroduction
Psychosocial stress is widely believed to be involved in
the development of functional somatic syndromes or
disorders (FSDs), such as chronic fatigue syndrome (CFS),
fibromyalgia (FM), and irritable bowel syndrome (IBS) [1–
3]. The autonomic nervous system (ANS) and hypothalamic-
pituitary-adrenal axis (HPA axis) both serve as bodily stress
responsive systems [4–6], and psychosocial stress may have
the potential to induce chronic under- or overactivity of these
stress responsive systems [7–9]. However, alterations in
stress responsive systems may not only be a result of
psychosocial stress, but may also be a consequence of factors
such as concurrent stress, smoking, obesity, medication use,
comorbid depressive disorder, or physical inactivity [10,11].A reason to investigate a potential etiological link between
dysfunction of stress responsive systems and FSDs emerges
from the idea that dysfunction of the ANS and HPA axis may
contribute to increased symptom experience [12–14]. The
question remains whether dysfunction of stress responsive
systems is actually present in FSDs, whether it is a generic or
FSD-specific factor, and whether it could be involved in their
etiology or is merely a consequence or epiphenomenon.
In this review, we will systematically assess whether
stress responsive system dysfunction satisfies the require-
ments of being a causal risk factor for FSDs, using a decision
tree proposed by Kraemer et al. [15]. In this decision tree, a
risk factor is defined as a measurable characterization of each
subject in a specified population that precedes the outcome
of interest. A characterization that satisfies all requirements
for a risk factor except for precedence is a correlate of the
outcome. This is crucial, because consequences of outcomes
are likely more highly correlated with the outcomes than are
risk factors. A risk factor that can change spontaneously
within a subject or that can be changed with an intervention
is a variable risk factor. The term causal risk factor can only
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outcome when it is manipulated (see Fig. 1). We will apply
this decision tree to the available literature on ANS and HPA
axis alterations in FSDs and studies on FSD-related clusters
of functional somatic symptoms (FSSs).ANS activity and FSDs
Are alterations in ANS activity correlated with FSDs?
A widely used proxy for ANS function is heart rate
variability (HRV), from which a measure of cardiac vagal
activity can be derived. A meta-analysis including 14
studies indicated statistically significant lower baseline
cardiac vagal activity in subjects with a FSD compared to
controls [16], with no apparent differences between CFS,
FM, and IBS. This meta-analysis thus suggests that
reduced parasympathetic activity possibly causes increased
arousal and is a generic correlate of FSDs. However,
sensitivity analyses also suggested the presence of
publication bias. Moreover, there was unexplained
heterogeneity in the effect sizes of studies included in
the meta-analysis, possibly related to a variety of
methodological shortcomings, including biased selection
of control subjects and potential confounding. A popula-
tion-based study published shortly afterwards, that
adjusted for factors such as gender, age, body mass
index, medication use, and physical inactivity, found
lower cardiac vagal activity in 30 CFS subjects compared
to 38 healthy controls, but this difference did not reach
statistical significance [17]. A population-based study on
FSSs in 774 adults demonstrated that decreased cardiac
vagal activity was associated with a higher number of
FSSs in young to middle-aged adults. Moreover, as was
the case in the meta-analysis, this association with lower
cardiac vagal activity was generic in the sense that is was
similar for different bodily clusters of FSSs (e.g., in the
musculoskeletal cluster resembling FM and the gastroin-
testinal cluster resembling IBS) [18]. In this population-
based study, an unanticipated interaction between age and
cardiac vagal activity was also found, in which the
association between cardiac vagal activity and FSS turned
positive for middle-aged to older adults. Interestingly,
these results seem to be in line with previously reported
age-associated differences in the association between
cardiac vagal activity and depression [19].
From the meta-analysis of ANS activity in rest, it was
clear that the large variety in methodological procedures
may have contributed to equivocal results. This variety is
even larger for studies investigating HRV measurements
performed during challenge tests. Strategies used to
challenge the ANS include measurements during standing,
tilt table testing, deep breathing, isometric exercise,
treadmill walking, thermal stimuli, rectal balloon distention,
and mental stress. Given the variety of challengeprocedures and the fact that reliability of HRV during
challenge tests is generally poorer than when measured at
rest [20], it is not surprising that results of studies towards
ANS activity during challenge in FSD patients are mixed.
In about half of the studies, no significant differences were
found between subjects with a FSD and healthy controls,
but in those studies that did find significant differences,
cardiac vagal activity was always lower or responsiveness
was decreased in FM and CFS, and most of the time in IBS
[11]. In summary, the available evidence suggests reduced
parasympathetic activity to be a generic correlate of FSSs
and FSDs.
Do alterations in ANS activity precede FSDs?
As the ANS innervates several organs, certain sensa-
tions and misinterpretation of peripheral physiological
arousal may result in the experience of FSSs [13,14].
Examples of FSS that may result from misinterpretation of
autonomic physiological arousal are functional abdominal
pain in case of decreased gastrointestinal peristalsis, and
functional musculoskeletal pain in case of increased
muscle tension. Although theoretically attractive, it should
be noted that studies investigating a relation between
changes in ANS activity and experience of symptoms on
the short-term are scarce. We are aware of one study that
assessed whether alterations in HRV directly precede
symptom experience. This study was performed in a
nonclinical student population of 18 young females scoring
high on a list of hyperventilation-related FSSs and 18
young females scoring low on this list. Although the group
high on FSSs reported a significantly larger number of
somatic symptoms after mental stress and breathing of
CO2-enriched air compared to the group low on FSSs,
there were no accompanying differences in cardiac vagal
activity [21]. Therefore, the authors argue that persons
scoring high on hyperventilation-related FSSs possibly
have an exaggerated perception of normal peripheral
physiology. However, this finding in a specific subgroup
of FSSs in healthy students should be replicated in larger
populations suffering from clinically relevant FSDs.
Longitudinal studies on whether alterations in ANS
activity precede FSDs in the long term are lacking. Available
evidence is restricted to the previously mentioned popula-
tion-based study on ANS activity and FSSs, which showed
that decreased cardiac vagal activity was associated with
FSSs after 2 years of follow-up in younger adults. Instead,
increased cardiac vagal activity was associated with FSSs
after 2-year follow-up in middle-aged to older adults [18].
Can ANS activity be changed and does change
improve FSDs?
Several medications influence ANS activity [22,23].
Furthermore, there is some preliminary evidence that
interventions such as HRV biofeedback [24] or
Fig. 1. The process of elucidation of risk factor status for a factor in a population for a particular outcome. Reprinted with permission from Arch Gen Psychiatry
1997;54:341.
463L.M. Tak, J.G.M. Rosmalen / Journal of Psychosomatic Research 68 (2010) 461–468meditation [25] can improve cardiac vagal activity.
Interestingly, the extent to which ANS activity can be
changed may differ by gender or age. For example,
exercise training resulted in significant increases in
cardiac vagal activity, but these effects were considerably
larger in younger compared to older subjects [26].
Gender also has a significant role in these exercise-
related changes in healthy young adults, as cardiac vagal
activity increased after training and decreased after
deconditioning in men, whereas no significant changes
were apparent in women [27].
To our knowledge, no study has assessed whether cardiac
vagal activity can be manipulated to change FSD outcome.Conclusions on the role of ANS activity in FSDs
A meta-analysis found lowered cardiac vagal activity in
subjects with a FSD, with apparently no differences between
CFS, FM, and IBS. When studies found differences, they
consistently demonstrated lower cardiac vagal activity in
patients with a FSD. Given the potential publication bias, the
overall poor methodological quality, and the lack of
longitudinal studies; however, it seems not possible yet to
firmly reject or accept a role of ANS dysfunction in FSDs, or
to differentiate its relative importance across the three FSDs.
A population-based study suggested that the results of the
meta-analysis on FSDs are not solely due to methodological
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as a generic risk factor for FSSs in younger adults. The
observation that lower cardiac vagal activity precedes new-
onset FSSs suggests that alterations in this stress responsive
system are not just a concomitant or consequence of FSS.
The finding of higher cardiac vagal activity in older adults
with FSS warrants further research and better insight. Based
on current available evidence, it seems premature to decide
whether ANS activity is a correlate of FSDs, let alone
whether it is a causal risk factor. Overall, evidence suggests
reduced parasympathetic activity as a generic factor, but the
inconclusive evidence on the role of the ANS in FSDs
requires further study.HPA axis activity and FSDs
Are alterations in the HPA axis correlated with FSDs?
The findings on the association between the HPA axis and
FSD are even more heterogeneous than in ANS studies. Not
only mild hypocortisolism or normal cortisol levels, but also
hypercortisolism, has been reported [11]. A recent meta-
analysis of cross-sectional studies demonstrated that hypo-
cortisolism was present in CFS and possibly in FM, but not
in IBS [28]. A relevant subgroup might constitute indivi-
duals with childhood trauma, as it has recently been found
that decreased cortisol responses to awakening are observed
only in those individuals with CFS who reported exposure to
childhood trauma but not in individuals without such
exposure [29].
In agreement with the meta-analysis, an experimental
study on 80 healthy young adults observed that those who
scored higher on subjective measures such as pain intensity
and pain unpleasantness had a flattened cortisol awakening
response (i.e., lower cortisol in the morning) [30]. A small
study that examined salivary cortisol levels of 14 healthy
office workers during four consecutive weeks also showed
that low cortisol levels in the morning and high cortisol
levels in the evening were associated with poor self-rated
health and fatigue [31]. Differences in the association
between cortisol and symptom clusters as found in the
meta-analysis on FSDs were not found in a population-based
study on FSSs in 741 adults. Taking the role of medication
and a large range of potential confounders into account, there
was no cross-sectional association between 24-h urinary
free cortisol (24-h UFC) and the total number of FSSs
experienced in the previous year [32]. In addition, 24-h UFC
excretion was not associated with the number of FSSs in any
of the bodily clusters.
HPA axis activity can also be measured after a challenge
test. A problem is the variety of applied challenges, as many
different pharmacological and non-pharmacological stres-
sors are used. Blunted responses and enhanced negative
feedback are the main findings in studies on HPA axis
function after challenge tests [11,33,34]. It is important torealize that rest and challenge measurements within a person
appear poorly interrelated. For example, the cortisol
awakening response and cortisol values after a psychosocial
stress test are not correlated [35]. This is surprising given the
general idea that those alterations may be representatives of
the same underlying HPA axis pathology. Thus, measuring
cortisol in rest may reveal other underlying mechanisms than
measuring cortisol after challenge tests. Even the naturalistic
cortisol awakening response and cortisol levels later in the
day are not driven by the same factors, as the genetic
influence on the cortisol awakening response is distinct from
the heritability of daytime cortisol levels [36]. In summary,
when alterations in the HPA axis were detected, hypocorti-
solism and blunted HPA axis responses were consistent
correlates of subgroups of FSDs. Since baseline and
challenge stress measurements seem to reflect different
processes, it is essential that their different meanings are
further elucidated to be able to interpret them appropriately
in the process of FSDs.
Do alterations in HPA axis activity precede FSD?
Although acute stress is known to produce analgesia,
chronic stress may have the opposite effect, a process
mediated by corticotrophin-releasing hormone (CRH)
[37,38]. Low cortisol concentration may cause widespread
pain and fatigue [12,39]. One study has closely examined
whether cortisol levels are related to the experience of FSSs
in the short term. In a sample of 121 participants middle-aged
adults, it was found that morning cortisol levels were not
predicted by prior-day levels of fatigue and physical
symptoms, whereas low morning cortisol predicted higher
levels of fatigue and physical symptoms later that day.
Authors concluded that these results are consistent with a
role of cortisol in physiological activation and an influence
on physical well-being [40].
The question whether alterations in HPA axis activity
predict FSDs in the long term has been subject of a number
of prospective studies. Studies focusing on fatigue in specific
groups at risk found no predictive role of cortisol in the
development of post-infectious unexplained fatigue in 71
primary care patients after 3 or 6 months [41], or in
postoperative unexplained fatigue in 161 patients undergo-
ing elective surgery after two days, three weeks, or six
months [42]. From a study on fatigue in the general
population, however, another picture emerges. Among a
group of 4299 former or current civil servants, low cortisol at
awakening predicted new-onset fatigue at follow-up approx-
imately 30 months later. The association with new-onset
fatigue was independent of factors such as age, gender, waist
circumference, smoking, alcohol use, medication use,
depressive symptoms, time of waking, sleep duration,
sleep disturbances, and stress on the day of sample
collection. Furthermore, persistent fatigue assessed two
years prior to cortisol measurement was not associated
with cortisol secretion, suggesting that the direction of the
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fatigue [43]. Long-term longitudinal studies have not been
restricted to unexplained fatigue, but have also been
performed in other subgroups of FSSs. Among a group of
subjects psychosocially at high risk for chronic widespread
pain, lower morning and higher evening salivary cortisol
levels predicted new onset of chronic widespread pain, a
condition related to FM [44]. The 24-h UFC excretion did
not predict development of new-onset FSSs in a 2-year
follow-up period in our previously mentioned population-
based study [32]. It should be noted that fatigue has not been
measured in this study.
Overall, a tentative picture emerges suggesting that a
flattened diurnal rhythm of cortisol (i.e., lower morning
cortisol and higher evening cortisol levels) is related to the
experience of FSSs or FSDs. The finding of the importance
of morning cortisol in somatization may not be surprising,
because timely cortisol secretion for mobilization of energy
resources is necessary to meet upcoming demands of the day
[45]. Recent reviews are beginning to elucidate the meaning
and relevance of the different aspects of the diurnal rhythm
of the HPA axis [46,47].
Can HPA axis activity be changed and does change
improve FSDs?
Several medications with the capacity to influence
cortisol levels via different pathways are documented
[48,49]. Some of these medications may not only confound
the association between cortisol and FSDs, but may also be
used to change cortisol levels intentionally as an interven-
tion. Psychological interventions also seem able to influence
HPA axis activity [50].
It has been tested whether treatment with hydrocortisone
improves the symptoms or disability caused by FSDs.
Randomized controlled trials have shown that low-dose
cortisol replacement therapy lead to short-term reductions in
fatigue in CFS [51,52]. Although pharmacologically raising
levels of cortisol can temporarily alleviate symptoms, it is
not recommended as treatment of choice in CFS. Reasons for
caution are a rapid loss of efficacy upon discontinuation, the
observation that only a minority of patients gain benefit, and
that no pre-treatment factors that predict response to
hydrocortisone are identified [33]. Whether the same applies
to FM and IBS is unknown. In FM, only one small study in
20 patients, performed over 20 years ago, showed that 10 mg
of prednisone daily was not effective over 20 years ago [53].
In IBS, treatment with corticosteroids has never been tested
in a trial [54].
The effect of psychological and behavioral interventions
on the HPA axis has also been tested in FSDs. Two studies in
CFS and FM observed that cognitive behavioral treatment
alone or in combination with exercise therapy resulted in
restoration of cortisol levels [55,56]. It should be noted that
neither study included a control group. Moreover, although
these two studies indicated that hypocortisolism in FSDs isreversible by treatment, they did not specifically examine
whether these alterations were due to reducing adverse
behavioral consequences, such as sleep disturbances,
physical inactivity, or pain experience. Cortisol levels may
also have a prognostic value, since it has been demonstrated
that lower daily cortisol output and a flattened diurnal
rhythm predict a poor response to cognitive behavioral
therapy in CFS [57]. Interestingly, it has also been reported
that CFS patients who respond less well to cognitive
behavioral therapy are the ones who are more persistently
physically inactive [58]. However, the question whether
non-responders with hypocortisolism in this study might
represent a physically inactive group has not been assessed
and remains to be answered. Preliminary evidence for
physical inactivity as a cause of hypocortisolism rather than a
confounder comes from a small study performed in 18
regularly exercising healthy adults. Subjects were asked to
discontinue their regular aerobics lessons for one week. The
subset of healthy subjects that developed symptoms of pain
and fatigue after exercise deprivation was characterized by
lower cortisol levels at baseline [59]. Authors of this study
speculated that the subset of healthy individuals with lower
cortisol levels unknowingly exercise regularly to augment
the function of HPA axis and thus suppress symptoms.
Conclusions on the role of HPA axis dysfunction in FSDs
The HPA axis is the most extensively investigated
stress responsive system in FSDs. A meta-analysis on this
subject found lower cortisol levels in CFS and, possibly in
FM, but not in IBS. Although HPA axis alterations are not
always found, when studies find differences, lower
morning cortisol levels in combination with a flatted
diurnal rhythm seems consistent with HPA axis alterations
in functional fatigue and musculoskeletal pain. Longitudi-
nal studies suggest that hypocortisolism is a specific risk
factor for fatigue and musculoskeletal FSSs. Whether
hypocortisolism also has a role in symptom maintenance
has not been specifically studied. Based on current
available evidence, hypocortisolism is at least a risk factor
in subgroups of FSDs. The question whether it also is a
causal risk factor remains to be answered.
Future directions for research on dysfunction of stress
responsive systems in FSDs
In summary, although hypocortisolism and decreased
cardiac vagal activity seem correlates of FSDs, several
studies have reported null-findings. An important issue is
that individual studies are often underpowered. As an
example, the reported effect size of d=0.32 in the meta-
analysis on cardiac vagal activity in FSDs implicates that in a
case-control study, a sample size of 155 in each group is
required for 80% power. However, the average sample size
of included primary studies was 24 cases (range 8–70), and
20 controls (range 8–38). Several other reasons have been
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such as heterogeneity in the patient groups, the lack of
epidemiologically comparable control groups, and failure to
appropriately adjust for relevant confounders [10,16].
To successfully proceed in this complex field, future
research faces the challenge of devising studies that include a
theoretical perspective as to why alterations in stress
responsive system function might influence the experience
of somatic symptoms. Whereas this review has focused on
peripheral (i.e., efferent) mechanisms, it is important to
realize that this peripheral input is modulated by central (i.e.,
afferent) mechanisms [60]. Disturbances in function of
central nervous system structures are increasingly considered
pivotal in the etiology of somatization [61–63]. For example,
alterations in activity of the anterior cingulate cortex, a
structure that is interconnected with both the ANS en HPA
axis, have been associated with pain experience and
somatization [60,62]. However, as findings are divergent,
the need to establish subgroups in this research area arises
[64]. In addition, carefully choosing the optimal methodo-
logical strategy is essential. Future studies could employ
methods that appropriately account for the time-varying
nature of the association by repeatedly assessing activity of
stress responsive systems, FSDs, and covariates like body
mass index, depression, anxiety, and health behaviors, such
as smoking, alcohol use, and physical inactivity, and factors
like childhood trauma and other psychosocial stressors [65].
When stress responsive system dysfunction is found to be
a causal risk factor for FSDs, its value in clinical or policy
applications remains to be evaluated. According to Cohen's
conventions, the magnitude of significant associations
between stress responsive system function and FSSs is
usually small [66]. However, the terms small, medium, and
large are relative, not only to each other, but even more
particularly to the area of research. With regard to
somatization, a plausible cause of small effect sizes is
heterogeneity in etiological mechanisms, inherent to many
associations studied in psychosomatic research. The fact that
an effect size is an average can be important. Whereas a
small overall effect size may raise questions about the
clinical relevance of the association, effect sizes may be
more substantial when studying relevant subgroups. The
importance of finding subgroups is illustrated by the
population-based study on cortisol and CFS, in which
hypocortisolism was only found in patients with childhood
trauma [29].
As it is costly to study stress responsive system function
in sufficiently large epidemiological cohorts, another
interesting way to promote understanding of dysfunction of
stress responsive systems as a causal risk factor of the
etiology of FSDs is doing research on treatment studies.
Using evidence-based treatments, this strategy may provide
information as to whether measures of stress responsive
system function predict treatment response or change when
the FSD improves. For example, hypocortisolism and a
flattened diurnal release of cortisol were associated with apoorer response to cognitive behavioral therapy in CFS [57],
suggesting that patients' neuroendocrine profile may be
relevant in choosing the optimal treatment strategy. Ulti-
mately, a risk factor can only be proven to be causal when it
has the ability to change the outcome in randomized
controlled trials. As a second step, therefore, the benefits
of treatments targeting stress-responsive system dysfunction
could be studied. Importantly, ignoring strong moderators of
treatment response may lead to inclusion of many subjects
for whom the interventions are not appropriate, or perhaps
are even harmful, and may attenuate effect sizes. In fact,
weak effects associated with various treatments for FSDs
[54,67] may be due to lack of information on moderators and
mediators of treatment. Instead, interventions should be
targeted to relevant subgroups [68].Concluding remarks
In conclusion, although not a condition sine qua non for
FSDs in general, stress responsive system dysfunction may
be involved in the etiology and treatment strategy in
subgroups of patients. Such subgroups need to be better
identified. As several studies begin to gather multiple
waves of stress responsive system data and important
covariates over the course of many years, the role of and
time scales over which changes contribute to FSDs should
be increasingly illuminated. This approach likely represents
the best strategy by which we can improve our under-
standing of this association.
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